RGB-5088

Phase 1Biologic

HHangzhou Reprogenix Bioscience, Inc

RGB-5088 is one of 42 biologic programs targeting Type 1 Diabetes Mellitus. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Type 1 Diabetes MellitusActive, not recruiting

Type 1 Diabetes MellitusPhase 1

Active, not recruiting

Competition

Competitive Landscape

249 competitors in Type 1 Diabetes Mellitus

#DrugCompanyPhaseTrials

Victoza

Novo Nordisk

Phase 3

4 2

Symlin

AstraZeneca

Phase 3

3 3

Tecfidera

Biogen

Phase 3

1 4

Galvus

Novartis

Phase 3

1 5

Suglat

Astellas

Phase 3

1 6

Inpefa

LLexicon Pharmaceuticals

Phase 3

5 7

Atacand

Simulect

Jardiance

3 10

Zegalogue

Zealand Pharma

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2031

Phase 1Recruiting

Type 1 Diabetes Mellitus

NCT06731218

Clinical

Trials by Indication[1]

Type 1 Diabetes Mellitus1 trial

Phase I Clinical Study to Evaluate the Safety and Efficacy of RGB-5088 in Patients With Type 1 Diabetes Mellitus

Recruiting·HHangzhou Reprogenix Bioscience, Inc·Phase 1·NCT06731218·10 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for RGB-5088. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — RGB-5088 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for RGB-5088. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Hangzhou Reprogenix Bioscience, Inc company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: HHangzhou Reprogenix Bioscience, Inc

RGB-5088

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2031

Trials by Indication[1]

Type 1 Diabetes Mellitus1 trial

References

Drug Info

Quick Facts

Related News